Michael J. Dillon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michael J. Dillon has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Chulananda Dias A Goonasekera
Department of Anaesthesiology, Faculty of Medicine, University of Peradeniya
6 shared publications V Shah
Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust, London, bCentre for Clinical Pharmacology, Cruciform Project, University College, London
5 shared publicationsVanita Shah
Department of Nephrourology, Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust, 30 Guilford Street, London WC1 N1EH, UK
3 shared publicationsC Daman Willems
2 shared publicationsM Uchiyama
2 shared publicationsA I Piqueras
Medical Unit, Institute of Child Health, London, UK
1 shared publication
Latest Publications
- Open Access
- 28 November 2009
- Published by Springer Nature in Pediatric Nephrology
- Vol. 25 (9) , 1641-1652
Medium-size-vessel vasculitis
Medium-size-artery vasculitides do occur in childhood and manifest, in the main, as polyarteritis nodosa (PAN), cutaneous PAN and Kawasaki disease. Of these, PAN is the most serious, with high morbidity and not inconsequential mortality rates. New classification criteria for PAN have been validated that will have value in epidemiological studies and clinical trials. Renal involvement is common and recent therapeutic advances may result in improved treatment options. Cutaneous PAN is a milder disease characterised by periodic exacerbations and often associated with streptococcal infection. There is controversy as to whether this is a separate entity or part of the systemic PAN spectrum. Kawasaki disease is an acute self-limiting systemic vasculitis, the second commonest vasculitis in childhood and the commonest cause of childhood-acquired heart disease. Renal manifestations occur and include tubulointerstitial nephritis and renal failure. An infectious trigger and a genetic predisposition seem likely. Intravenous immunoglobulin (IV-Ig) and aspirin are effective therapeutically, but in resistant cases, either steroid or infliximab have a role. Greater understanding of the pathogenetic mechanisms involved in these three types of vasculitis and better long-term follow-up data will lead to improved therapy and prediction of prognosis.
- 28 November 2009
- Published by Springer Nature in Pediatric Nephrology
- Vol. 25 (9) , 1641-1652
Open AccessMedium-size-vessel vasculitis
Medium-size-artery vasculitides do occur in childhood and manifest, in the main, as polyarteritis nodosa (PAN), cutaneous PAN and Kawasaki disease. Of these, PAN is the most serious, with high morbidity and not inconsequential mortality rates. New classification criteria for PAN have been validated that will have value in epidemiological studies and clinical trials. Renal involvement is common and recent therapeutic advances may result in improved treatment options. Cutaneous PAN is a milder disease characterised by periodic exacerbations and often associated with streptococcal infection. There is controversy as to whether this is a separate entity or part of the systemic PAN spectrum. Kawasaki disease is an acute self-limiting systemic vasculitis, the second commonest vasculitis in childhood and the commonest cause of childhood-acquired heart disease. Renal manifestations occur and include tubulointerstitial nephritis and renal failure. An infectious trigger and a genetic predisposition seem likely. Intravenous immunoglobulin (IV-Ig) and aspirin are effective therapeutically, but in resistant cases, either steroid or infliximab have a role. Greater understanding of the pathogenetic mechanisms involved in these three types of vasculitis and better long-term follow-up data will lead to improved therapy and prediction of prognosis.
- 24 January 2008
- Vol. 10 (3) , 313-24
Hypertension in children.
- 13 April 2007
- Vol. 25, S66-8
Henoch-Schönlein purpura: recent advances.
Recent developments in relation to Henoch-Schönlein purpura (HSP) include: a) a proposed new classification of childhood vasculitides including new classification criteria for HSP; b) the identification of various, potentially important, genetic polymorphisms in HSP that may be relevant in terms of predisposition to or protection from complications; c) evidence that prophylactic steroid at the onset of disease does not protect against renal or gastrointestinal complications but does seem to have beneficial effects in treating them.
- 13 April 2007
- Vol. 25, S66-8
Henoch-Schönlein purpura: recent advances.
Recent developments in relation to Henoch-Schönlein purpura (HSP) include: a) a proposed new classification of childhood vasculitides including new classification criteria for HSP; b) the identification of various, potentially important, genetic polymorphisms in HSP that may be relevant in terms of predisposition to or protection from complications; c) evidence that prophylactic steroid at the onset of disease does not protect against renal or gastrointestinal complications but does seem to have beneficial effects in treating them.
- 4 July 2006
- Published by Springer Nature in Pediatric Nephrology
- Vol. 21 (9) , 1219-1222
A new international classification of childhood vasculitis
There has been, for many years, a need for an acceptable classification of childhood vasculitis as well as criteria for classifying specific sub-categories of vasculitic disease affecting the young. Hitherto, there has been, with certain exceptions, much reliance on adult classification systems and criteria that have not proved entirely satisfactory. A recent International Consensus Conference held in Vienna in June 2005 attempted to rectify this state of affairs. It resulted in a new proposal for childhood vasculitis classification and proposals of classification criteria for several important categories of childhood vasculitis including Henoch–Schonlein purpura, Kawasaki disease, polyarteritis nodosa (with additionally definitions for cutaneous and microscopic polyarteritis), Wegener granulomatosis and Takayasu arteritis. The process involved the Delphi technique to gather a wide spectrum of opinion from pediatric rheumatologists and nephrologists followed by the Consensus Conference attended by a group of pediatricians with extensive vasculitis experience where nominal group techniques were utilized to agree on a general classification and classification criteria for individual childhood vasculitides. The consensus that was reached will hopefully provide pediatricians with a valuable tool in the study of childhood vasculitides but will require appropriate validation using patient and control groups.
- 4 July 2006
- Published by Springer Nature in Pediatric Nephrology
- Vol. 21 (9) , 1219-1222
A new international classification of childhood vasculitis
There has been, for many years, a need for an acceptable classification of childhood vasculitis as well as criteria for classifying specific sub-categories of vasculitic disease affecting the young. Hitherto, there has been, with certain exceptions, much reliance on adult classification systems and criteria that have not proved entirely satisfactory. A recent International Consensus Conference held in Vienna in June 2005 attempted to rectify this state of affairs. It resulted in a new proposal for childhood vasculitis classification and proposals of classification criteria for several important categories of childhood vasculitis including Henoch–Schonlein purpura, Kawasaki disease, polyarteritis nodosa (with additionally definitions for cutaneous and microscopic polyarteritis), Wegener granulomatosis and Takayasu arteritis. The process involved the Delphi technique to gather a wide spectrum of opinion from pediatric rheumatologists and nephrologists followed by the Consensus Conference attended by a group of pediatricians with extensive vasculitis experience where nominal group techniques were utilized to agree on a general classification and classification criteria for individual childhood vasculitides. The consensus that was reached will hopefully provide pediatricians with a valuable tool in the study of childhood vasculitides but will require appropriate validation using patient and control groups.
- 9 March 2006
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 165 (6) , 351-357
Vasculitis treatment – new therapeutic approaches
In childhood, vasculitis carries with it a not inconsequential morbidity and mortality. Current therapy is usually effective in inducing remission, but there is a penalty in terms of significant and serious side effects as well as concerns about long-term maintenance regimens. Additionally, some patients are recalcitrant to treatment and options have, hitherto, been limited in relation to alternative therapy. In view of this, novel therapeutic approaches are being explored that include the better use of long-established agents as well as the utilization of newer immunosuppressive and immunomodulatory strategies. Blockade of circulating mediators and surface receptors as well as lymphocyte depletion and immunoablation are being introduced predominantly in adults but increasingly also in children. With greater understanding of the pathogenetic mechanisms involved in the disease processes it is becoming possible to utilize much more focussed therapy for these serious and life-threatening disorders with, hopefully, a decrease in long-term morbidity and mortality as well as a diminution of drug-induced adverse effects.
- 9 March 2006
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 165 (6) , 351-357
Vasculitis treatment – new therapeutic approaches
In childhood, vasculitis carries with it a not inconsequential morbidity and mortality. Current therapy is usually effective in inducing remission, but there is a penalty in terms of significant and serious side effects as well as concerns about long-term maintenance regimens. Additionally, some patients are recalcitrant to treatment and options have, hitherto, been limited in relation to alternative therapy. In view of this, novel therapeutic approaches are being explored that include the better use of long-established agents as well as the utilization of newer immunosuppressive and immunomodulatory strategies. Blockade of circulating mediators and surface receptors as well as lymphocyte depletion and immunoablation are being introduced predominantly in adults but increasingly also in children. With greater understanding of the pathogenetic mechanisms involved in the disease processes it is becoming possible to utilize much more focussed therapy for these serious and life-threatening disorders with, hopefully, a decrease in long-term morbidity and mortality as well as a diminution of drug-induced adverse effects.
- 1 November 2002
- Published by Springer Nature in Pediatric Nephrology
- Vol. 17 (11) , 943-949
The usefulness of renal vein renin studies in hypertensive children: a 25-year experience
Lateralised renin secretion predicts improvement following surgery/angioplasty of the affected kidney in paediatric hypertension. We retrospectively analysed all our renal vein renin (RVR) studies undertaken in hypertensive children and their subsequent clinical outcomes over a 25-year period. The outcomes were categorised as cure, improvement or no change in hypertension. The proportions that benefited by 'following' or 'ignoring' the RVR results in relation to the aetiology of hypertension and subsequent therapy were compared. A ratio between the RVR value of the dominant kidney and that of the contralateral kidney (R/Rc ratio) above 1.5 was considered to show significant lateralisation. A ratio between RVR value of the contralateral kidney and that of the caudal inferior vena cava (Rc/P ratio) of less than 1.3 was considered to indicate contralateral renin suppression. Of 233 RVR records, 137 were suitable for analysis. Of these, 39 had reflux nephropathy (RN), 73 renovascular disease (RVD) and the others miscellaneous conditions. Of the 39 hypertensive children with RN, the R/Rc ratio was over 1.5 in 20 subjects, of whom 11 underwent surgery. Amongst the 19 with an R/Rc less than 1.5, 4 also had surgery. Of the 73 hypertensive children with RVD, the R/Rc ratio was over 1.5 in 38 subjects, of whom 20 underwent surgery/angioplasty. Amongst the 35 with an R/Rc less than 1.5, 7 also underwent surgery/angioplasty. In RN there was no significant difference in the proportion that improved with allocated treatment, as suggested by the 'test' when compared with those who were 'misallocated'. In RVD, however, the proportion improved (35.0%) by 'following the test' (i.e. R/Rc ratio) was significantly greater than the proportion improved (12.5%) in the group in whom the test was 'ignored'. This was true for both R/Rc and Rc/P ratios. Thus, RVR measurements are useful for identifying hypertensive children with RVD that may have a favourable outcome after surgery, but this does not apply to children with RN. Measurements, however, may have diagnostic value even if surgery or angioplasty is not anticipated.
- 1 November 2002
- Published by Springer Nature in Pediatric Nephrology
- Vol. 17 (11) , 943-949
The usefulness of renal vein renin studies in hypertensive children: a 25-year experience
Lateralised renin secretion predicts improvement following surgery/angioplasty of the affected kidney in paediatric hypertension. We retrospectively analysed all our renal vein renin (RVR) studies undertaken in hypertensive children and their subsequent clinical outcomes over a 25-year period. The outcomes were categorised as cure, improvement or no change in hypertension. The proportions that benefited by 'following' or 'ignoring' the RVR results in relation to the aetiology of hypertension and subsequent therapy were compared. A ratio between the RVR value of the dominant kidney and that of the contralateral kidney (R/Rc ratio) above 1.5 was considered to show significant lateralisation. A ratio between RVR value of the contralateral kidney and that of the caudal inferior vena cava (Rc/P ratio) of less than 1.3 was considered to indicate contralateral renin suppression. Of 233 RVR records, 137 were suitable for analysis. Of these, 39 had reflux nephropathy (RN), 73 renovascular disease (RVD) and the others miscellaneous conditions. Of the 39 hypertensive children with RN, the R/Rc ratio was over 1.5 in 20 subjects, of whom 11 underwent surgery. Amongst the 19 with an R/Rc less than 1.5, 4 also had surgery. Of the 73 hypertensive children with RVD, the R/Rc ratio was over 1.5 in 38 subjects, of whom 20 underwent surgery/angioplasty. Amongst the 35 with an R/Rc less than 1.5, 7 also underwent surgery/angioplasty. In RN there was no significant difference in the proportion that improved with allocated treatment, as suggested by the 'test' when compared with those who were 'misallocated'. In RVD, however, the proportion improved (35.0%) by 'following the test' (i.e. R/Rc ratio) was significantly greater than the proportion improved (12.5%) in the group in whom the test was 'ignored'. This was true for both R/Rc and Rc/P ratios. Thus, RVR measurements are useful for identifying hypertensive children with RVD that may have a favourable outcome after surgery, but this does not apply to children with RN. Measurements, however, may have diagnostic value even if surgery or angioplasty is not anticipated.
- 1 September 2002
- Published by Springer Nature in Pediatric Nephrology
- Vol. 17 (9) , 754-761
Clinical features in 17 paediatric patients with Wegener granulomatosis
The aim of this report was to describe childhood patients with Wegener granulomatosis (WG) from one centre, to analyse the variety of clinical manifestations seen and compare the data with other published paediatric and adult series. The records of 17 patients with WG who were under the care of Great Ormond Street Hospital for Children (GOSH) from 1981 to 1998 were reviewed. We analysed presenting features before admittance to GOSH and the clinical signs observed whilst the children were under the care of the hospital. Of 17 patients, 13 were females and there was a male/female ratio of 1:3.25. Among the patients there were 2 sisters. The age of the patients at disease onset varied from 2 weeks to 14 years. The median/mean age was 6/6.3 years. American College of Rheumatology criteria for diagnosing WG were fulfilled in 11 of 17 patients. The frequency of different system involvement was: respiratory 87%, kidneys 53%, sinuses 35%, joints 53%, eyes 53%, nervous system 12%, skin 53%. cANCA was positive in 10 patients (59%), but pANCA was negative in all measured sera. Kidneys were involved in 2 of 8 patients (25%) with the disease onset from 0 to 5 years and in 7 of 9 patients (78%) with the disease onset from 6 to 14 years (PP<0.05). Colchicine as a supplement to prednisolone and cytotoxic/immunosuppressant drugs was used effectively in 5 patients.
- 1 September 2002
- Published by Springer Nature in Pediatric Nephrology
- Vol. 17 (9) , 754-761
Clinical features in 17 paediatric patients with Wegener granulomatosis
The aim of this report was to describe childhood patients with Wegener granulomatosis (WG) from one centre, to analyse the variety of clinical manifestations seen and compare the data with other published paediatric and adult series. The records of 17 patients with WG who were under the care of Great Ormond Street Hospital for Children (GOSH) from 1981 to 1998 were reviewed. We analysed presenting features before admittance to GOSH and the clinical signs observed whilst the children were under the care of the hospital. Of 17 patients, 13 were females and there was a male/female ratio of 1:3.25. Among the patients there were 2 sisters. The age of the patients at disease onset varied from 2 weeks to 14 years. The median/mean age was 6/6.3 years. American College of Rheumatology criteria for diagnosing WG were fulfilled in 11 of 17 patients. The frequency of different system involvement was: respiratory 87%, kidneys 53%, sinuses 35%, joints 53%, eyes 53%, nervous system 12%, skin 53%. cANCA was positive in 10 patients (59%), but pANCA was negative in all measured sera. Kidneys were involved in 2 of 8 patients (25%) with the disease onset from 0 to 5 years and in 7 of 9 patients (78%) with the disease onset from 6 to 14 years (PP<0.05). Colchicine as a supplement to prednisolone and cytotoxic/immunosuppressant drugs was used effectively in 5 patients.
- Open Access
- 1 September 2002
- Published by BMJ in Archives of Disease in Childhood
- Vol. 87 (3) , 229-230
Erythromelalgia: an endothelial disorder responsive to sodium nitroprusside
Erythromelalgia is an unusual syndrome of painful vasodilatation. Aetiopathology is probably different in children and adults. Presentation can be severe and associated with hypertension. Dramatic benefit from infused nitroprusside suggests the disorder could represent a dysfunctional endothelium.
- 1 September 2002
- Published by BMJ in Archives of Disease in Childhood
- Vol. 87 (3) , 229-230
Open AccessErythromelalgia: an endothelial disorder responsive to sodium nitroprusside
Erythromelalgia is an unusual syndrome of painful vasodilatation. Aetiopathology is probably different in children and adults. Presentation can be severe and associated with hypertension. Dramatic benefit from infused nitroprusside suggests the disorder could represent a dysfunctional endothelium.
- 1 April 2002
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 69 (Suppl_2) , SII121
Henoch-Schonlein purpura (treatment and outcome).
- 1 April 2002
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 69 (Suppl_2) , SII121
Henoch-Schonlein purpura (treatment and outcome).
- 2 May 2001
- Published by Springer Nature in Pediatric Nephrology
- Vol. 16 (5) , 460-462
Henoch-Schönlein purpura with antiphospholipid antibodies following an influenza vaccination: commentary
- 2 May 2001
- Published by Springer Nature in Pediatric Nephrology
- Vol. 16 (5) , 460-462
Henoch-Schönlein purpura with antiphospholipid antibodies following an influenza vaccination: commentary